Bernstein raises Cigna stock price target on 2027 growth outlook
Bernstein raised Cigna's (CI) price target to $390, citing 2027 growth outlook and undervaluation. CI trades at $303.13, 5% below 52-week high. Q3 2026 earnings beat estimates, with revenue at $73.7B and adjusted EPS at $7.98. CI raised full-year EPS outlook to $30.60.
How this was made
The 30-second read
Why it matters
The upgrade and earnings beat provide fresh, material information that could drive short-term buying interest in CI.
Market read
Cigna's earnings beat and higher guidance, combined with an analyst target raise, create a bullish catalyst for the stock and may influence the broader health insurance sector.
What to watch
Potential regulatory scrutiny on pharmacy benefits could temper upside.
Background
Bernstein SocGen Group adjusted its price target for Cigna after the insurer posted Q3 2026 results that beat expectations and raised its full-year earnings outlook.
Ticker impact
Bernstein raised its price target on Cigna to $390 and reported Cigna's Q3 2026 earnings beat and raised full-year guidance.
likely upward pressure as the market prices in the higher target and stronger guidance
Target increase and earnings beat are fresh primary disclosures for a large-cap insurer, indicating improved outlook.
Market effects
Positive signal for health insurance sector as earnings beat may lift peers.
U.S. market may see modest gains in financials.
Limited to U.S. insurers, no broad global effect.
Counterpoint
Some investors may view the modest target raise as insufficient given long-term margin pressures in PBM.
Key entities
- companyCigna Group
U.S. health services insurer (ticker CI).
- analystBernstein SocGen Group
Research firm that raised the price target.


